Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. (GBT) is a pioneering biopharmaceutical company headquartered in the United States, with a focus on developing innovative treatments for sickle cell disease and other blood disorders. Founded in 2011, GBT has made significant strides in the industry, particularly with its flagship product, Oxbryta (voxelotor), which uniquely targets the underlying cause of sickle cell disease by increasing haemoglobin's affinity for oxygen.
With a commitment to transforming the lives of patients, GBT has established a strong market position, recognised for its dedication to research and development in the haematology sector. The company continues to expand its operational reach, aiming to address unmet medical needs and improve patient outcomes globally. Through its innovative approach and robust pipeline, Global Blood Therapeutics is at the forefront of advancing therapies that enhance the quality of life for individuals affected by blood disorders.
+44 vs industry average
Global Blood Therapeutics, Inc.’s score of 82 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Global Blood Therapeutics, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Reported emissions
No reported emissions data is available for Global Blood Therapeutics, Inc. yet.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Global Blood Therapeutics, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Global Blood Therapeutics, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Pfizer Inc.
Carbon Disclosure Project
Inherited from Pfizer Inc.The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Pfizer Inc.RE 100
Inherited from Pfizer Inc.Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project